Neurocrine Biosciences Inc
(STU:NB3)
€
153.15
-1.9 (-1.23%)
Market Cap: 15.37 Bil
Enterprise Value: 14.57 Bil
PE Ratio: 26.83
PB Ratio: 5.14
GF Score: 93/100 Neurocrine Biosciences Inc at Bank of America Global Healthcare Conference Transcript
May 12, 2026 / 06:20PM GMT
Release Date Price:
€132.25
(+3.48%)
Tazeen Ahmad
Bank of America - Analyst
(audio in progress) analysts at the bank. It's my pleasure to have with me our next presenting company, Neurocrine. Sitting up here on stage, there are a couple of familiar faces, Matt Abernethy, who is, of course, Chief Financial Officer; as well as Todd Tushla, your job again, sir?
Todd Tushla
Neurocrine Biosciences Inc - Investor Relations
I'm still -- I'm the current Vice President of Investor Relations.
Tazeen Ahmad
Bank of America - Analyst
Okay. Just wanted to clarify.
Matthew Abernethy
Neurocrine Biosciences Inc - Chief Financial Officer
You did tell me this new title from you this morning is his favorite person. Can you confirm that?
Tazeen Ahmad
Bank of America - Analyst
We'll put that on your card. So maybe, Matt, for a few people who aren't as familiar with the company, can you just give us a quick overview of Neurocrine? And then we can go into some of the more recent
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot